<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03251326</url>
  </required_header>
  <id_info>
    <org_study_id>6971</org_study_id>
    <secondary_id>U54DA037842</secondary_id>
    <nct_id>NCT03251326</nct_id>
  </id_info>
  <brief_title>Nabilone in Cannabis Users With PTSD</brief_title>
  <official_title>Effects of Nabilone on Trauma Related Cue Reactivity in Cannabis Users With PTSD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite the prevalence of cannabis use among the PTSD population and self-reports that it is
      used to help cope with PTSD symptoms, the direct effects of cannabis on PTSD symptomology are
      unknown. The purpose of this placebo-controlled, within-subject study is to assess the
      effects of smoked cannabis and orally administered nabilone, a synthetic analog of THC, the
      primary psychoactive component of cannabis on multiple dimensions of PTSD symptomatology in
      cannabis smokers with PTSD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will compare the effects of smoked cannabis and nabilone on attentional bias
      toward trauma- related stimuli, subjective and emotional processing to a range of trauma-and
      non-trauma-related images and physiological reactivity to these stimuli in individuals with
      CUD and PTSD. Importantly, this study will also probe the abuse related potential of nabilone
      compared to smoked cannabis in this population, a critical aspect in determining the
      potential feasibility for its use clinically to treat CUD in PTSD populations. The effects of
      nabilone will be compared to propranolol as a positive control.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>All patients will contribute to each of 4 drug conditions (placebo, nabilone, smoked cannabis, and propranolol).</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cue Reactivity</measure>
    <time_frame>1 month</time_frame>
    <description>Emotional Stroop Task</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Cannabis</condition>
  <condition>Post Traumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>Nabilone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nabilone capsules (4 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propranolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Propranolol capsules (40mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Smoked cannabis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(0.0 and 5.6% THC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nabilone</intervention_name>
    <description>Nabilone capsules (4 mg)</description>
    <arm_group_label>Nabilone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabis</intervention_name>
    <description>Cigarettes (0.0 and 5.6% THC)</description>
    <arm_group_label>Smoked cannabis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <description>Propranolol capsules (40mg)</description>
    <arm_group_label>Propranolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current cannabis use

          -  PTSD symptoms

          -  Able to give informed consent and comply with study procedures

          -  Women who are normally cycling and practicing an effective form of birth control other
             than hormonal contraceptives

        Exclusion Criteria:

          -  Meeting criteria for certain current psychiatric disorders

          -  Clinical laboratory tests outside of normal limits

          -  History of clinically significant cardiac or respiratory diagnoses

          -  Current parole or probation

          -  Women who are currently pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Margaret Haney, PhD</last_name>
    <phone>6467746129</phone>
    <email>meg.haney@nyspi.columbia.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Haney, PhD</last_name>
      <phone>646-774-7777</phone>
      <email>meg.haney@nyspi.columbia.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2017</study_first_submitted>
  <study_first_submitted_qc>August 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2017</study_first_posted>
  <last_update_submitted>August 14, 2017</last_update_submitted>
  <last_update_submitted_qc>August 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
    <mesh_term>Dronabinol</mesh_term>
    <mesh_term>Nabilone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

